Amidst of COVID-19 outbreak, Infinium wishes to extend its support to the industry by offering 30% discount on its market research reports across all license formats.
Request Discount
Loading...
COVID-19! We are now including the impact analysis of the COVID-19 on Biologics Market report and the forecast period of this report shall be revised to 2020-2026. The section on the impact of COVID-19 on this market is included in the report for free. To know more Request a Sample of this report.

Biologics Market (Product - Monoclonal Antibodies, Vaccines, Recombinant Proteins, and Others (antisense, RNAi & Molecular Therapy Products); Therapy Areas - Autoimmune, Antidiabetics, Oncologics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

  • Published : May, 2020

  • Rep Id : HC0851

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the biologics market provides in-depth analysis of segments and sub-segments in the global as well as regional biologics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional biologics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global biologics market. According to the report, the global biologics market is projected to grow at a CAGR of 10.7% over the forecast period of 2020-2026.

 

Market Insight

Biologics drugs are made from living organisms. Biologics are relatively large and complex molecules compared with conventional chemical drugs. They are composed of proteins, carbohydrates, nucleic acids, or combinations of these substances. They currently target diseases with very limited or no available treatment options such as several types of cancers, autoimmune diseases, and other non-communicable diseases. Biologics have several potential advantages as they can be tailored to hit specific targets in the human body. Presently, more than 300 biologic medicines have been brought to the market.

 

The growing prevalence of cancer and several autoimmune diseases is a key driver facilitating the growth of the biologics market. Moreover, a rise in incidence is also expected due to an increase in exposure to risk factors. This is expected to create potential demand for these drugs over the forecast period. Furthermore, increasing investments by the pharmaceutical giants in the biologics segment is also expected to fuel the expansion of the market. Several biologic drugs are in development and are expected to be launched in the coming years which will significantly aid the growth of the market. However, the high cost of the drugs remains a major hindrance factor for its large scale adoption. Nonetheless, increasing production is projected to lower the cost of these drugs in the long term. Moreover, a surging number of biologic APIs and their growing penetration into multiple therapy areas such as asthma, dyslipidemia, and allergy will create multiple growth opportunities for the biologics market.  The current concerns over the spread of coronavirus are expected to have a moderate impact on the growth of the biologics market as the sale of companies whose products rely heavily on elective and non-essential procedures are expected to be hurt censoriously. Additionally, these biologics are considered immunosuppressing because they work on different immune system pathways to curtail the inflammation that occurs in these chronic conditions, which can make patients more vulnerable to different kinds of infection. Thereby, lowering the administration of such drugs. However, the market will accelerate quickly over the end of 2020.

 

Among the regions, North America holds a major share in the global biological drugs market. Growing technological advancements, favorable regulatory policies and increasing awareness about the biologics are the major factors that drive the growth of the North American biologics market. Moreover, the increasing prevalence of chronic illnesses such as cancer and diabetes are anticipated to boost the adoption of biologics in North America. Europe is anticipated to hold the second largest share owing to the presence of a large geriatric population in countries such as Germany and The United Kingdom.

 

Segment Covered

The report on the global biologics market covers segments such as product, and therapy areas. On the basis of product, the sub-markets include monoclonal antibodies, vaccines, recombinant proteins, and others (antisense, RNAi & molecular therapy products). On the basis of therapy areas, the sub-markets include autoimmune, antidiabetics, oncologics, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as F Hoffman La Roche, Eli Lilly & Company, Samsung Biologics, Celltrion Inc., Amgen Inc., Abbvie Inc., Sanofi S.A., Pfizer Inc., Novo Nordisk A/S, and Johnson & Johnson Services Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of biologics market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount